16 results about "Manic Disorders" patented technology

Provided herein are optionally substituted pyrazolylacetamides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating diseases or disorders, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania, tinnitus, neurodevelopmental diseases or disorders, a smooth muscle contractility disorder, Dravet syndrome, posttraumatic stress disorder (PTSD), with such compounds and pharmaceutical compositions.

Provided herein are optionally substituted pyrazolylacetamides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating diseases or disorders, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania, tinnitus, neurodevelopmental diseases or disorders, a smooth muscle contractility disorder, Dravet syndrome, posttraumatic stress disorder (PTSD), with such compounds and pharmaceutical compositions.

Provided herein are optionally substituted benzimidazole-1, 2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 related diseases with such compounds and pharmaceutical compositions, these diseases are, for example, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperactivity, dyskinesia, dyskinesia, mania and tinnitus.

Embodiments of the present invention relate generally to the treatment of schizophrenia or bipolar I disorder, and more particularly to the administration of iloperidone, including escalating doses of iloperidone, a pharmaceutically acceptable salt of iloperidone, an active metabolite of iloperidone, or a pharmaceutically acceptable salt of a metabolite of iloperidone, in such treatment. A first aspect of the present invention provides a method of treating a patient suffering from bipolar I disorder, comprising administering to the patient an effective amount of iloperidone, a pharmaceutically acceptable salt of iloperidone, an active metabolite of iloperidone, or a pharmaceutically acceptable salt of a metabolite of iloperidone, wherein the effective amount is effective to improve at least one manic symptom in the patient.

The invention provides application of bifidobacterium longum subsp. Longum MNH-19749 in preparation of products for preventing and treating nervous system diseases, and relates to the technical field of biological medicines. The bifidobacterium longum subsp. Longum MNH-19749 is obtained through long-term strain screening research, and the bifidobacterium longum subsp. Longum MNH-19749 has a better relieving effect on mania, epilepsy, Parkinson's disease and other nervous system diseases. Experiments prove that the inactivated bacteria of the bifidobacterium longum subsp. Longum MNH-19749 can effectively relieve dysfunction of biological models of nervous system diseases such as mania, epilepsy and Parkinson's disease, so that a new basis is provided for immunotherapy of patients with the nervous system diseases, and the bifidobacterium longum subsp. Longum MNH-19749 has good research significance and application prospects.

The invention belongs to the technical field of patient body constraining, and particularly discloses mania psychiatric patient body constraining equipment which comprises a supporting mechanism, a flexible weightless leg supporting mechanism and an automatic jacking mechanism, the supporting mechanism comprises a cushion, a bottom steel frame and a moving assembly, the bottom steel frame is arranged below the cushion, and the moving assembly is arranged below the cushion. A backrest is arranged on the cushion, the moving assembly is arranged on the bottom steel frame, and the automatic jacking mechanism is arranged on the bottom steel frame. By means of the flexible weightlessness type leg supporting mechanism and the automatic jacking mechanism, when a patient struggles up, swing brake supporting can be automatically completed by means of the weight of the patient, that is, the patient cannot stand up due to weightlessness and no supporting point; the supporting mechanism can be stabilized and fixed through supporting of the automatic jacking mechanism; therefore, the technical purpose of binding the patient on the cushion can be achieved under the condition that all-directional binding and fixing are not carried out.

Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and / or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.

Embodiments of the present invention generally relate to the treatment of schizophrenia or bipolar type I disorders, and more particularly, to the administration of iloperidone in such treatments, including the titration administration of iloperidone, a pharmaceutically acceptable salt of iloperidone, an active metabolite of iloperidone, or a pharmaceutically acceptable salt of an iloperidone metabolite. A first aspect of the invention provides a method of treating a patient suffering from a bipolar type I disorder, the method comprising administering to the patient an effective amount of iloperidone, a pharmaceutically acceptable salt of iloperidone, an active metabolite of iloperidone, or a pharmaceutically acceptable salt of an iloperidone metabolite, wherein the effective amount is an amount effective to ameliorate at least one symptom of mania in the patient.

The application discloses a benzodihydrofuran compound, a pharmaceutical composition thereof and application. The application provides a compound as shown in formula I or a pharmaceutically acceptable salt thereof. The compound has a sedative effect and helps to relieve the mania symptoms of patients with mental diseases.

Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.

A method of treatment of mental disorder of a subject includes the steps of: normalizing an expression of both DRD1 and DRD5, which belong to DRD1-like family, of the subject to a preset standard level. The DRD1 / 5 level and expression can be increased or decreased bidirectionally by targeting an upstream promoter sequence of DRD1 / 5. The promoter activity of DRD1 / 5 can be attenuated by using an antipsychotic which directly targets the DRD1 / 5 promoter. The antipsychotics being used are typical and / or atypical antipsychotic medications such as Haloperidol,Risperidone, Clozapine and Cariprazine. The treatment is also useful for the subject with an impaired constitutive expression of DRD1 / 5 gene. The method can be used to treat schizophrenia, autism, depression, mania and bipolar disorders by normalizing the DRD1 / 5 expression level. The promoter gene sequencing of DRD1 and / or DRD5 can also be used for quantitative mental health screening through comparing with a standard sequence database.

Embodiments include a method of treating mania comprising administering to a patient at least one dose of a composition comprising magnesium and lidocaine; determining whether the patient exhibits a warm sensation after administering at least one dose of the composition; under the condition that the patient shows the warm feeling, waiting for the patient shows that the warm feeling disappears; and verifying whether mania has decreased to a predetermined level after the patient indicates that the warm sensation has disappeared.

The invention discloses a benzodihydrofuran compound as well as a pharmaceutical composition and application thereof. The invention provides a compound shown as a formula I or pharmaceutically acceptable salt thereof. The compound disclosed by the invention has a sedative effect and is beneficial to relieving manic symptoms of patients with mental diseases. # imgabs0 #

Embodiments include a method for treating mania which includes bolusing at least one dose to a patient of a composition which comprises magnesium and lidocaine; determining whether the patient indicates a warm feeling in response to bolusing the at least one dose of the composition; waiting for the patient to indicate that the warm feeling has gone away in response to the patient indicating the warm feeling; and verifying that the mania is reduced to a predetermined level in response to waiting for the patient to indicate that the warm feeling has gone away.

The invention discloses an aminothiazole compound and application thereof as a brain-permeable histamine H2 receptor stimulant, and belongs to the field of medicines. The structural general formula of the aminothiazole compound provided by the invention is as shown in formula (I), and the aminothiazole compound comprises pharmaceutically acceptable salts. The aminothiazole compound disclosed by the invention has histamine H2 receptor agonistic activity and excellent blood-brain barrier permeability. Therefore, the compound can be applied to preparation of drugs for treating diseases such as schizophrenia, mania, attention deficit hyperactivity disorder, autism or greedy neurosis, autism, Parkinson's disease, ischemic brain injury and the like. # imgabs0 #

The application discloses an amino thiazole compound and use thereof as a brain-permeable histamine H2 receptor agonist, and belongs to the field of medicines. The amino thiazole compound provided by the application has a structural general formula as shown in formula (I) and includes pharmaceutically acceptable salts. The amino thiazole compound has histamine H2 receptor agonistic activity and excellent blood-brain barrier permeability. Therefore, the amino thiazole compound can be applied to preparation of a medicine for treating diseases such as schizophrenia, mania, attention deficit hyperactivity disorder, binge eating or bulimia nervosa, autism, Parkinson's disease, ischemic brain injury and the like.